Mohanlal’s film has brought a bigger occupancy on the third day than the opening day! On the opening day the film registered a morning occupancy of 48%, followed by the same during the afternoon!

which targeted the SIRPα receptor with which CD47 interacts. Last year, AbbVie also pulled out of a $1.3 billion R&D partnership with I-Mab on lemzoparlimab for MDS and AML, for undisclosed ...

G protein-coupled receptors (GPCRs) are integral membrane proteins with seven membrane-spanning helices. Upon binding to a ligand – which can range from small molecules like cyclic AMP to ...

The company’s lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 ...

Pattern recognition receptors (PRRs) are expressed by cells in the body in order to sense molecules that are associated with infection or tissue damage. They are important for activating the ...

These receptors are found throughout your body. Endocannabinoids bind to them in order to signal that the ECS needs to take action. There are two main endocannabinoid receptors: CB1 receptors ...

Serotonin (5-hydroxytryptamine [5-HT]) receptor subtypes, such as the 5-HT 1A receptor, are considered to mediate the ability of antipsychotic drugs to enhance cognition. On the other hand ...

Two years after AstraZeneca splashed out $1 billion upfront for rights to Daiichi Sankyo's TROP2-targeting antibody-drug conjugate DS-1062, the drug has generate promising results in advanced non ...

Image credit: T Schneider / Shutterstock. ALX Oncology’s CD47-blocker evorpacept, in combination with MSD’s blockbuster Keytruda (pembrolizumab), has failed to show benefit in two Phase II trials. The ...

Am J Health Syst Pharm. 2011;68(15):1419-1425. The short duration of activity of naloxone when the drug is administered as an i.v. bolus may limit its effectiveness for the management of OIP ...